When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

The current Wall Street sell-off has wiped out billions in market value, hammering tech giants, banks, and airlines while ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Ignored stocks’ outperform as Big Tech and banks slide ...

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected ... biotech Halozyme Therapeutics (HALO.O), opens new tab, the Wall Street Journal reported on Wednesday, citing people familiar with ...

Telehealth companies like Hims & Hers (HIMS) are aggressively marketing hair-loss medications to young men, with some patients saying they ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...